Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.

Authors

Toni Choueiri

Toni K. Choueiri

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Toni K. Choueiri , Piotr Tomczak , Se Hoon Park , Balaji Venugopal , Tom Ferguson , Stefan N. Symeonides , Jaroslav Hajek , Yen-Hwa Chang , Jae-Lyun Lee , Naveed Sarwar , Antoine Thiery-Vuillemin , Marine Gross-Goupil , Mauricio Mahave , Naomi B. Haas , Piotr Sawrycki , Tian Zhang , Lei Xu , Kentaro Imai , Christian Heinrich Poehlein , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03142334

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 679)

DOI

10.1200/JCO.2023.41.6_suppl.679

Abstract #

679

Poster Bd #

H11

Abstract Disclosures

Similar Posters

First Author: Toni K. Choueiri

First Author: Toni K. Choueiri

Poster

2018 ASCO Annual Meeting

Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC.

Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC.

First Author: Alain Ravaud